Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEGANT: elacestrant versus standard endocrine therapy in high-risk ER-positive HER2-negative early breast cancer
NL-OMON59850Phase 3Active, not recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Apr 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by Stemline Therapeutics. Primary endpoint: Invasive breast cancer-free survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59850.